Patent classifications
C12N9/26
ALPHA-AMYLASE VARIANTS HAVING IMPROVED PERFORMANCE AND STABILITY
The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION
The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
Compositions for Producing Glucose Syrups
The present invention relates to a method of making glucose syrup from liquefied starch comprising, (a) contacting the liquefied starch with a glucoamylase, a pullulanase, and optionally an alpha-amylase wherein the ratio of pullulanase dose expressed as NPUN/gDS, to alpha-amylase dose expressed as FAU(A)/gDS is at least 60, particularly at least 75, particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 250, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 800 or if no alpha-amylase is present the pullulanse is present in a dose of at least 0.5, particularly at least 0.75, particularly at least 1.0, particularly at least 1.5 NPUN/gDS, and (b) saccharifying the liquefied starch.
MALTOTRIOSE-GENERATING AMYLASE
A maltotriose-generating amylase has an amino acid sequence of any one three polypeptides. One or more amino acids can be substituted, added, inserted, or deleted, such that the polypeptides have at least 70% sequence identity with the amino acid sequences of the polypeptides. The polypeptides are encoded by DNA, which can be included in recombinant vectors. Transformants can be obtained by transforming a host with the DNA.
Yeast expressing heterologous glucoamylase
The present disclosure concerns recombinant yeast host cell for saccharification of a biomass. The recombinant yeast host cell has a genetic modification for expressing a heterologous polypeptide having glucoamylase activity (Rasamsonia emersonii glucoamylase). In some embodiments, the heterologous polypeptide comprises the signal sequence associated with the alpha-mating 1 factor. The present disclosure also concerns a process for saccharification of a biomass using the recombinant yeast host cell as well as a process for fermenting the saccharified biomass into a fermentation product.
MODULATION OF NADPH GENERATION BY RECOMBINANT YEAST HOST CELL DURING FERMENTATION
The present disclosure concerns recombinant yeast host cells having a first genetic modification for downregulating a first metabolic pathway that converts NADP.sup.+ to NADPH, as well as a second genetic modification for upregulating a second metabolic pathway that converts NADP.sup.+ to NADPH. The second genetic modification allows the expression of a glyceraldehyde-3-phosphate dehydrogenase lacking phosphorylating activity, which can, in some embodiments, be from enzyme commission 1.2.1.9 or 1.2.1.90. The second pathway is distinct from the first metabolic pathway. The present disclosure also concerns a process for making and improving the yield of a fermented product, such as ethanol, using the recombinant yeast host cell.
OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
METHOD FOR CONSTRUCTING TREHALOSE MULTI-ENZYME COMPLEX IN VITRO MEDIATED BY ARTIFICIAL SCAFFOLD PROTEIN
The present disclosure relates to a method for constructing a trehalose polyenzyme complex in vitro by mediation of an artificial scaffold protein, which mainly comprises the following steps: constructing a recombinant bacterium WB800n-ScafCCR for self-assembled scaffold protein module; constructing a recombinant bacterium WB800n-P43-phoD-treY-Ccdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-treZ-Ctdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-cgt-Rfdoc for self-assembled catalytic module; secretorily expressing the recombinant bacteria and self-assembling in vitro to obtain a recombinant trehalose multi-enzyme complex. The trehalose multi-enzyme complex constructed by the method of the present disclosure has a higher catalytic efficiency in preparing trehalose than that of mixed free enzymes, and the method can be used for production of high quality trehalose after immobilization with cellulose microspheres.
DIGITAL MICROBIOLOGY
Methods, compositions, and kits are provided for rapidly analyzing microbial growth and/or number in a plurality of water-in-oil emulsion droplets.
COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE
A recombinant adeno-associated virus (rAAV) useful for treating type II glycogen storage disease (Pompe) disease is provided. The rAAV comprises an AAV capsid which targets cells of at least one of muscle, heart, kidney, and the central nervous system and which has packaged therein a vector genome comprising a nucleic acid sequence encoding a a chimeric fusion protein comprising a signal peptide and a vIGF2 peptide fused to a human acid-α-glucosidase hGAA780I protein under the control of regulatory sequences which direct its expression. Also provided are methods of making and using this rAAV.